BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Redeemable Preferred Stock And Shareholders' Equity

Consolidated Statements Of Redeemable Preferred Stock And Shareholders' Equity - USD ($) $ in Thousands	Total	Series E Convertible Preferred Stock	June 2020 Warrants	July 2020 Warrants	Series F Convertible Preferred Stock	Common Stock	Common Stock Series E Convertible Preferred Stock	Common Stock Series F Convertible Preferred Stock	Additional Paid-in Capital	Additional Paid-in Capital Series E Convertible Preferred Stock	Additional Paid-in Capital June 2020 Warrants	Additional Paid-in Capital July 2020 Warrants	Additional Paid-in Capital Series F Convertible Preferred Stock	Convertible Preferred Stock Series F Convertible Preferred Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit	Mezzanine Equity Series E Convertible Preferred Stock	Mezzanine Equity Series G Preferred Stock [Member]
Balance at Dec. 31, 2019	$ 377					$ 1			$ 235,624						$ (701)	$ (234,547)	$ 3,965
Balance, shares at Dec. 31, 2019						1,258,000											70,000
Conversion of convertible preferred stock		$ 3,965					$ 0	$ 2		$ 3,965			$ 16,969	$ (16,971)			$ (3,965)
Conversion of convertible preferred stock, shares							278,000	1,712,000						(17,000)			(70,000)
Sale of common stock, net	3,798					$ 1			3,797
Sale of common stock, net, shares					17,000	432,000
Sale of common stock warrants			$ 3,031	$ 9,450							$ 3,031	$ 9,450
Stock offering costs	(856)								856
Stock-based compensation	2,591								2,591
Deemed dividend on convertible preferred stock													(17,378)	$ 17,378
Issuance of stock from RSUs, net	163								163
Issuance of stock from RSUs, net, share						74,000
Warrant issued in connection with debt instruments	67								67
Issuance of convertible preferred stock in rights offering, net of offering costs					$ 2,411									$ 2,411
Issuance of convertible preferred stock in rights offering, net of offering costs, shares														18,000
Deemed Dividend on Convertible Preferred Stock	(17,378)
Beneficial conversion on Convertible Preferred Stock													2,700	$ (2,700)
Exercise of common stock warrants	1,544								1,544
Common stock warrants exercised, shares						154,000
Net loss	(16,829)															(16,829)
Foreign currency translation adjustment	316														316
Balance at Dec. 31, 2020	10,028					$ 4			261,667					$ 118	(385)	(251,376)
Balance, shares at Dec. 31, 2020					882	3,908,000								1,000
Conversion of convertible preferred stock													630	$ (630)
Conversion of convertible preferred stock, shares								63,000						(1,000)
Sale of common stock, net	13,291					$ 1			13,290
Sale of common stock, net, shares					1,000	560,000
Exercise of stock options, net	$ 132								132
Exercise of stock options, net, shares	14,000					14,000
Issuance of common stock for settlement of liability	$ 510								510
Issuance of common stock for settlement of liability, shares						20,000
Issuance of Restricted Shares	164								164
Issuance of Restricted Shares, shares						10,000
Stock-based compensation	2,416								2,416
Deemed dividend on convertible preferred stock					$ 500								(546)	$ 546
Issuance of stock from RSUs, net, share						145,000
Deemed Dividend on Convertible Preferred Stock	(546)
Exercise of common stock warrants	15,063					$ 1			15,062
Common stock warrants exercised, shares						1,429,000
Net loss	(16,158)															(16,158)
Foreign currency translation adjustment	(238)														(238)
Balance at Dec. 31, 2021	25,208					$ 6			293,325					34	(623)	(267,534)
Balance, shares at Dec. 31, 2021		0			251	6,149,000
Balance at Dec. 31, 2021	25,208
Conversion of convertible preferred stock													251	(251)
Conversion of convertible preferred stock, shares								25,000
Sale of common stock, net	5,602					$ 1			5,601
Sale of common stock, net, shares						679,000
Issuance of Restricted Shares	109								109
Issuance of Restricted Shares, shares						20,000
Stock-based compensation	2,117								2,117
Deemed dividend on convertible preferred stock					$ 200
Issuance of stock from RSUs, net, share						123,000
Issuance of convertible preferred stock in rights offering, net of offering costs, shares																		154,000
Deemed Dividend on Convertible Preferred Stock	(217)												$ (217)	$ 217
Temporary Equity Stock Redemption During Period Shares																		(154,000)
Phant Award Reclass	596								596
Exercise of common stock warrants	1					$ 1
Common stock warrants exercised, shares						727,000
Net loss	(28,634)															(28,634)
Foreign currency translation adjustment	$ (110)														(110)
Balance at Dec. 31, 2022						$ 8			$ 301,782						$ (733)	$ (296,168)
Balance, shares at Dec. 31, 2022		0				7,723,000